Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Climb Bio (CLYM) Receivables - Accured (2021 - 2025)

Climb Bio filings provide 5 years of Receivables - Accured readings, the most recent being $1.3 million for Q1 2025.

  • Quarterly Receivables - Accured changed N/A to $1.3 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Mar 2025, changed N/A year-over-year, with the annual reading at $1.1 million for FY2024, 179.75% up from the prior year.
  • Revenue - Other hit $2.8 million in Q3 2024 for Climb Bio, up from $1.5 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $1.3 million in Q1 2025 and bottomed at $100000.0 in Q4 2022.
  • Average Receivables - Accured over 5 years is $462230.8, with a median of $300000.0 recorded in 2021.
  • Peak annual rise in Revenue - Other hit 120.86% in 2024, while the deepest fall reached 33.78% in 2024.
  • Climb Bio's Revenue - Other stood at $1.3 million in 2023, then surged by 120.86% to $2.8 million in 2024.
  • Per Business Quant, the three most recent readings for CLYM's Receivables - Accured are $1.3 million (Q1 2025), $1.1 million (Q4 2024), and $990000.0 (Q3 2024).